Journals / Hacettepe Journal of Biology and Chemistry / 2011 / Cilt: 39 - Sayı: 3

Otoimmun hastalıklar ve immunoadsorpsiyon tedavisi

Autoimmune diases and immunoadsorption therapy

Pages
213–229
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, some selected applications on immunoadsorption therapies mainly for removal of anti-dsDNA antibodies from systemic lupus erythematosus (SLE) and rheumatoid factors from rheumatoid arthritis patients plasmas are briefly discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The human immune system is structured to recognize, respond to, and destroy a wide variety of potentially harmful microorganisms.
📊
Key Findings & Data:During the mid 1970’s the first application of therapeutic intervention with immunoadsorbents was reported.
💡
Conclusion & Impact:In this review, some selected applications on immunoadsorption therapies mainly for removal of anti-dsDNA antibodies from systemic lupus erythematosus (SLE) and rheumatoid factors from rheumatoid arthritis patients plasmas are briefly discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The human immune system is structured to recognize, respond to, and destroy a wide variety of potentially harmful microorganisms. One major component of this defense system depends on its ability to recognize foreign antigens versus healthy cells or tissues. When the immune system begins to destroy vital cells and organs within the body, the resulting reaction can be the basis for certain autoimmune diseases. Immunoadsorption, an extracorporeal technique for the removal of autoantibodies from patient plasma, offers some advantages over plasmapheresis. Immunoadsorption appeared relatively rapid and safe for the extensive removal of pathogenic antibodies and immune-complexes. During the mid 1970’s the first application of therapeutic intervention with immunoadsorbents was reported. In this review, some selected applications on immunoadsorption therapies mainly for removal of anti-dsDNA antibodies from systemic lupus erythematosus (SLE) and rheumatoid factors from rheumatoid arthritis patients plasmas are briefly discussed.

Özet

İnsan bağışıklık sistemi, zararlı olabilecek bir çok mikroorganizmayı tanıma, karşılık verme ve yok etmeye yönelik düzenlenmiştir. Bu savunma sisteminin temel bileşeni, sağlıklı hücre ve dokulardan yabancı antijenleri ayırt edebilme özelliğine dayanmaktadır. Bağışıklık sisteminin vücut içerisindeki önemli hücre ve dokuları yok etmeye başlamasıyla oluşan reaksiyon belirli bir otoimmun hastalığa sebep olabilmektedir. Hasta plazmasından otoantibadilerin uzaklaştırılması için uygulanan bir ekstrakorporal teknik olan immunoadsorpsiyon, plazmafereze göre önemli avantajlar sunmaktadır. İmmunoadsorpsiyon, patojenik antibadilerin ve immunkomplekslerin uzun süreli uzaklaştırılmasında daha hızlı ve güvenilirdir. İmmunoadsorpsiyonla ilk terapötik müdahele 1970’lerin ortalarında uygulanmıştır. Bu derlemede, sistemik lupus eritematos’lu ve romatoid artrit’li plazmalarından anti-dsDNA antibadilerin ve romatoid faktörlerinin uzaklaştırılması için uygulanılan immunoadsorpsiyon tedavilerine ait seçilen bazı makaleler kısaca tartışılmıştır.

🔖

Cite This Article

DENİZLİ, A. (2022). Otoimmun hastalıklar ve immunoadsorpsiyon tedavisi. Hacettepe Journal of Biology and Chemistry, Cilt: 39 - Sayı: 3, 213–229. https://ajindex.com/articles/529233

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. H.D. Massey, R.A. McPherson, Human leukocyte antigen: the major histocompatibility complex of man, in: Henry’s Clinical Diagnosis and Management by Laboratory Methods, W.B. Saunders, 2006
  2. S.G. O’Neill, L. Schrieber, Immunotherapy of systemic lupus erythematosus, Autoimmunity Reviews, 2005
  3. D.P. D’Cruz, M.A. Khamastra, G.R.V. Hughes, Systemic lupus erythematosus, Lancet, 369 (2007) 587
  4. D.S. Terman, I. Stewart, A. Hofmann, R.Carr, R. Harbeck, Specific removal of DNA antibody with an immunoadsorbent, Experientia, 30 (1974) 1493
  5. D.S. Terman, I. Stewart, J. Robinette, R. Carr, R. Harbeck, specific removal of DNA antibodies in vivo with an extracorporeal immuno-adsorbent, Clin. Exp. Immunol., 24 (1976) 231
  6. D.S. Terman, G. Buffaloe, C. Mattioli, G. Cook, R. Tilquist, M. Sullivan, J.C. Ayus, Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus, Lancet, ii (1979) 824
  7. P.K. Ray, Extracorporeal adsorption of pathologic gammaglobulins and immune complexes in various diseases including cancer, Plasma Ther. Transfus. Technol., 4 (1984) 289
  8. I.M. Nilsson, S.B. Sundquist, A. Ahlberg, S.E. Bergentz, A procedure for removing high titer antibodies by extracorporeal protein A-sepharose adsorption in hemophilia, Blood, 58 (1981) 38
  9. I.M. Nilsson, S.B. Sundquist, R. Ljung, L. Holmberg, C. Friburghaus, G. Björlin, Suppression of secondary antibody response by intraveneous immunoglobulin in a patient with hemophilia B and antibodies, Scand. J. Haematol., 30 (1983) 458
  10. H. Hoshimoto, H. Tsuda, Y. Kanai, S. Kobayashi, S. Hirose, H. Shinoura, R. Yokahari, M. Kinoshita, Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with SLE, J. Rheumatol., 18 (1990) 545
  11. A. Palmer, T. Cairns, F. Dische, G. Gluck, P. Gjorstrup, V. Parons, K. Welsh, D. Taube, Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, Nephrol. Dial. Transplant., 6 (1991) 536
  12. C.W. Wiesenhutter, B.L. Irish, J.H. Bertram, Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial, J. Rheumatol., 21 (1994) 804
  13. A. Deodhar, E. Allen, K. Daoud, I. Wahba, Vasculitis secondary to staphylococcal protein A immunoadsorption treatment in rheumatoid arthritis, Semin. in Arthritis Rheum., 31 (2002) 3
  14. B. Mugnier, P. Poullin, P. Lefevre, J. Roudier, Clinical improvem